he purpose of this report was to update the 2006 International League Against Epilepsy (ILAE) report and identify the level of evidence for long-term efficacy or effectiveness for antiepileptic drugs (AEDs) as initial monotherapy for patients with newly diagnosed or untreated epilepsy. All applicable articles from July 2005 until March 2012 were identified, evaluated, and combined with the previous ysis (Glauser et al., 2006) to provide a comprehensive update.
The prior ysis methodology was utilized with three modifications: (1) the detectable noninferiority boundary approach was dropped and both failed superiority studies and prespecified noninferiority studies were yzed using a noninferiority approach, (2) the definition of an adequate comparator was clarified and now includes an absolute minimum point estimate for efficacy/effectiveness, and (3) the relationship table between clinical trial ratings, level of evidence, and conclusions no longer includes a recommendation column to reinforce that this review of efficacy/evidence for specific seizure types does not imply treatment recommendations.
This evidence review contains one clarification: The commission has determined that class I superiority studies can be designed to detect up to a 20% absolute (rather than relative) difference in the point estimate of efficacy/effectiveness between study treatment and comparator using an intent-to-treat ysis. Since July, 2005, three class I randomized controlled trials (RCT) and 11 class III RCTs he been published. The combined ysis (1940-2012) now includes a total of 64 RCTs (7 with class I evidence, 2 with class II evidence) and 11 meta-yses.
New efficacy/effectiveness findings include the following: levetiracetam and zonisamide he level A evidence in s with partial onset seizures and both ethosuximide and valproic acid he level A evidence in children with childhood absence epilepsy.
There are no major changes in the level of evidence for any other subgroup. Levetiracetam and zonisamide join carbamazepine and phenytoin with level A efficacy/effectiveness evidence as initial monotherapy for s with partial onset seizures. Although ethosuximide and valproic acid now he level A efficacy/effectiveness evidence as initial monotherapy for children with absence seizures, there continues to be an alarming lack of well designed, properly conducted epilepsy RCTs for patients with generalized seizures/epilepsies and in children in general.
These findings reinforce the need for multicenter, multinational efforts to design, conduct, and yze future clinically relevant adequately designed RCTs. When selecting a patient's AED, all relevant variables and not just efficacy and effectiveness should be considered.
查看信源定址
- 2022-04-25照护质量控制成互联网照护“红绿灯”,三大环节促进线上照护质量提升
- 2022-04-252013年国际上抗癫痫联合会抗癫痫药使用指南
- 2022-04-13智能手机真能成为诊断工具吗?未必!
- 2022-04-12【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 2022-04-112013国际抗癫痫联合会抗癫痫药用指南
- 2022-04-07预测癫痫患者再入院风险
- 【用药问答】癫痫发作和局限性发作的首选治疗是什么?
- 著名女演员愤怒地告诉莆田妇科医院 要求在全国媒体上公开道歉
- 2013国际抗癫痫联合会抗癫痫药用指南
- 预测癫痫患者再入院风险
- 综述:癫痫持续状态诊治最新进展
- 临床试验显示XenoPort 银屑病药物胃肠道副作用较严重
- 抗癫痫药物预防新发癫痫:任重而道远
- 【预约直播】铿锵的论道 不炎,越来越多--「郁金香论坛」学术沙龙即将举行
- 癫痫治疗障碍仍难以克服
- 癫痫患者停药问题解决了吗?最新的预测模型已经发布!
- JCC:炎性肠病患者的间质和肉芽肿性肺病的发病率
- Neurology:颅脑损伤增加了迟发性癫痫的风险,高损伤频率、重伤、老年人尤其是
- 月经期间能喝茶吗? 女性月经期间能喝茶吗?
- 元宵节吃汤圆送灯
- 癫痫患者手术评估新型工具
- 脑梗死的症状是什么有这些前兆要谨慎
- 不注意这些问题,吃多少药都没用!
- FDA批准开浦兰治疗1个月至4岁癫痫儿童
- 2015第31届国际癫痫大会(IEC)
- 如何最有效地去除黑头?
- 小葫仙历险记夏秋交学雨季养生11
- 成人羊角风病的病因是什么?
- 为什么要定期复查脑电图?
- 注意┃要好好照顾,不仅可以避免妇科疾病,还有助于怀孕!
- 高考食谱 吃对食物,实现高考梦(13)
- 癫痫猝死:凶手是谁?
- Circ ep:心电图机自动诊断可能漏诊均QTc延长者
- 羊癫疯治疗方法有哪些 五个治疗方法视觉效果好
- 癫痫病吃完什么好
- Circ Ep:左室肥厚的腹水患者新发房颤增加SCD风险
- PLoS ONE:新的合成蛋白能快速激活癌细胞抵御流感
- 癫痫病有哪些哮喘呢
- 早期癫痫病症状展示出是什么
- 大咖直播—6 大公益援助详解:国际癫痫关爱日,症状最高可获 10 万元手术费用减免
- 40年内只报道25由此可知 癫痫致双侧股骨颈骨折该咋整?
- 亚甲基四氢叶酸还原酶缺陷随之而来的家族性癫痫性脑病
- 癫痫病诱发的主要成因是什么
- 儿童癫痫病的发病病征
- 初期癫痫病不该采用什么方法来治疗呢
- 延迟型癫痫发作病患卒中预后更差